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Abstract
Fanconi Anemia (FA) is a rare genetic disorder, characterized by progressive bone marrow failure and increased
predisposition to cancer. Despite being highly heterogeneous, all FA patients are hypersensitive to alkylating
agents, in particular to 1,2:3,4-diepoxybutane (DEB), and to oxidative damage. Recent studies point to defective
mitochondria in FA cells, which is closely related with increased production of reactive oxygen species (ROS) and
concomitant depletion of antioxidant defenses, of which glutathione is a well-known biomarker.
The objective of the present work is to evaluate the putative protective effect of α-lipoic acid (α-LA), a
mitochondrial protective agent, and N-acetylcysteine (NAC), a direct antioxidant and a known precursor for
glutathione synthesis, in spontaneous and DEB-induced chromosome instability (CI) in lymphocyte cultures from
FA patients.
For that purpose, lymphocyte cultures from 15 FA patients and 24 healthy controls were pre-treated with 20 μM
α-LA, 500 μM NAC and α-LA plus NAC at the same concentrations, and some of them were exposed to DEB
(0.05 μg/ml). A hundred metaphases per treatment were scored to estimate the relative frequency of spontaneous
and DEB-induced chromosome breakage.
The obtained results revealed that a cocktail of α-LA and NAC can drastically improve the genetic stability in FA
lymphocytes in vitro, decreasing CI by 60% and 80% in cultures from FA patients and FA mosaic/chimera patients,
respectively. These results suggest that the studied cocktail can be used as a prophylactic approach to delay
progressive clinical symptoms in FA patients caused by CI, which can culminate in the delay of the progressive
bone marrow failure and early cancer development.
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Introduction
Fanconi Anemia (FA) is a rare genetic disorder charac-
terized by chromosome instability (CI), several congeni-
tal malformations, progressive bone marrow failure, and
increased predisposition to cancer, particularly acute my-
elogenous leukemia [1]. Genetically, FA is a highly het-
erogeneous disease with 15 genes so far characterized
and cloned (FA-A, B, C, D1, D2, E, F, G, I, J, L, M, N, O,
P) [2] and that appears to influence genomic stability.
The clinical manifestations and the onset of disease are
also extremely variable. However, all FA patients have, in
common, unique markers that characterize the disease:
hypersensitivity to the clastogenic effect of DNA cross-
linking agents, in particular to diepoxybutane (DEB), [3]
and hypersensitivity to oxidative damage [4].
DEB-induced cytotoxicity, despite hitherto not com-
pletely understood, has been related to oxidative damage
and to glutathione (GSH) depletion [5-7]. The activation
of the mitochondrial apoptotic pathway in the event of
DEB-induced oxidative stress (OS) was more recently
demonstrated [8]. Importantly, DEB-induced DNA-DNA
and DNA-protein cross-links [9] are characteristic fea-
tures of ROS-mediated damage. In accordance to the in-
volvement of mitochondria and OS in the mechanisms
of DEB toxicity, we have recently demonstrated that
acute exposure to DEB both causes glutathione (GSH)
depletion and loss of ATP, followed by cell death in lym-
phocytes collected from healthy humans [10].
The role of oxygen and oxidative damage in FA cells
was described for the first time by Nordenson [11] fol-
lowed by Joenje et al [12]. Two years later, Joenje and
Oostra [13] established a direct correlation between high
tensions of oxygen and increased damage in FA lympho-
cytes. A direct association of OS with the primary gen-
etic defect in FA was suggested through the interaction
of the FANCC protein with NADPH cytochrome P450
reductase [14] and glutathione S-transferase [15], two
enzymes involved in the detoxification of reactive inter-
mediates. At least FANCC, FANCG and FANCA have
been shown to be associated with redox-related imbalance
and to a unique functional and structural sensitivity to OS
[16] and, altogether, these proteins are also related with mi-
tochondrial dysfunction [14-18]. Recently, Mukhopadhyay
et al [18] reported that FANCG protein physically inter-
acts with the mitochondrial peroxidase peroxiredoxin 3
(PRDX3), FA-G cells display distorted structures, and FA-A,
-C and -G have PRDX3 cleavage and decreased peroxid-
ase activity.
Mitochondrial dysfunction ultimately leads to oxida-
tive modifications of DNA, proteins and lipids. It is
recognized that FA cells show abnormal accumulation of
8-hydroxy-2’-deoxyguanosine (8-OHdG), a sub-product
of oxidative DNA damage, and also a mutagenic substance
by itself [19]. However, Castillo et al [20] concluded that
the FA pathway is redundant for the repair of oxidative
DNA damage (7,8-dihydro-8-hydroxyguanine, 8-oxoG).
Therefore, the accumulation of 8-oxoG in FA cells re-
flects sustained ROS overproduction rather than defective
processing of oxidized bases. These evidences, altogeth-
er, point towards a pro-oxidant state associated with
dysfunctional mitochondria, in FA cells (reviewed by
Pagano et al) [4].
Some studies have been performed testing the use of
antioxidants for decreasing chromosome damage in FA
cells. Dallapiccola et al [21] obtained a partial correc-
tion of CI in FA lymphocytes treated with the antioxi-
dants sodium ascorbate, L-cysteine, 2-mercaptoethanol,
α-mercaptopropionylglycine, and GSH. Later, the same
group [22] extended this study to desferoxamine, also
with partial correction of CI. Pincheira et al [23] demon-
strated that Vitamin E decreases the frequency of chromo-
somal damage and the duration of G2 in FA lymphocytes.
Some in vivo studies were also performed in animal
models. Zhang et al [24] showed that dietary supple-
ments with antioxidants can delay the age of onset of
epithelial tumors in FA mouse models. More recently,
this group [25] also demonstrated that the antioxidant
resveratrol maintains Fancd2(−/−) KSL cells in quies-
cence, improves the marrow microenvironment, partially
corrects the abnormal cell cycle status, and significantly
improves the spleen colony-forming capacity of Fancd2
(−/−) bone marrow cells. In spite of the promising re-
sults from previous studies, no therapy using antioxidants,
megavitamins, or micronutrients has been shown to be ef-
fective in treatment of FA, using evidence-based criteria.
Thus, further studies with new protective agents are re-
quired for the application of drugs with high effectiveness.
Among a number of potential candidate molecules
with antioxidant properties, some can be identified as
“mitochondrial nutrients” and substances that normalize
GSH balance. α-Lipoic acid (α-LA) is a natural and en-
dogenous compound that occurs in mitochondria and is
an essential cofactor for many mitochondrially localized
enzyme complexes. Furthermore, α-LA features a cyclic
disulfide moiety which exists in redox equilibrium with
its reduced dithiol form, dihydrolipoic acid. Dihydroli-
poic acid acts in GSH replenishment and is a potent
antioxidant in a redox-cycling environment, by reducing
vitamin C, vitamin E and coenzyme Q10 [26,27]. Previ-
ous studies also proved that α-LA can be a protective
agent against clastogenic [28] and genotoxic agents [29].
N-acetylcysteine (NAC), the acetylated variant of the
amino acid L-cysteine, is an excellent source of sulfhy-
dryl groups, and is converted in the body into metabo-
lites capable of stimulating GSH synthesis, promoting
detoxification, and acting directly as free radical scaven-
gers [30]. Recently, a study from Yadavilli et al [8] showed
that NAC has the ability to inhibit ROS production and
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apoptosis induced by DEB in human lymphoblasts. Im-
portantly, there are some clinical studies referring the
benefit of the combined use of α-LA and NAC by amelior-
ating the hematological response in advanced cancer patients
[31] and in the event of muscle-damaging exercise [32].
In a previous study [10], we showed that α-LA and
NAC have a partial protective effect on acute DEB-
induced toxicity to normal human lymphocytes, though
the effect of these compounds in CI of lymphocytes has
never been tested before. Thus, the aim of the present
work was to evaluate the putative protective effect of
α-LA and NAC, in spontaneous and DEB induced CI lym-
phocytes cultures from FA patients.
Methods
Subjects
This study includes 15 FA patients, referred by several
Hospitals, and already diagnosed with certainty on the
basis of DEB-induced cytogenetic tests, and 24 healthy
donors (HD), recruited among healthy male and female
donors, aged 20–40 years. The study was approved by
the Ethical Committe of Hospital Geral de Santo Antó-
nio, CHP, Porto. All procedures were done with the writ-
ten informed consent of the participants.
Cells and cell cultures
From each HD participant, 10 ml of venous blood was
collected by antecubital venipuncture, into vacuum tubes
with lithium heparin. From FA patients, 3 ml to 6 ml of
venous blood were collected, depending on the age and
healthy conditions of the patients, into vacuum tubes
with lithium heparin.
Whole blood (0.5 ml) was cultured in RPMI 1640
(Sigma) complete medium supplemented with 15% fetal
calf serum (GIBCO), antibiotics (10,000 units/ml of pen-
icillin and 10,000 μg/ml of streptomycin) (GIBCO) and
29 mg/ml of L-glutamine (Sigma). Cultures were stimu-
lated with 5 μg/ml of phytohemagglutinin (GIBCO) and
placed in an incubator at 37°C with 5% CO2 atmosphere,
for 72 h.
Exposure to DEB
DEB ((±)-1,2:3,4-diepoxybutane, [298-18-0], D-7019 Lot
34 H3683, Sigma), prepared in RPMI 1640, was added
to lymphocyte cultures 24 h after their initiation, thus
exposing cells to the chemical for 48 h. In lymphocyte
cultures from FA patients, DEB was added at the con-
centration of 0.05 μg/ml (the same concentration used
in the diagnostic test). As the lymphocytes from HD
are not so sensitive to DEB at that concentration, and
have variable responses, 3 higher concentrations were
used to obtain a significant toxic response (see Figure 1
for a description of DEB-induced CI pattern in HD and
FA patients). Therefore, a concentration of 0.1 μg/ml was
selected in cultures from 5 individuals (HD1-5), a con-
centration of 0.2 μg/ml was selected in cultures from 11
individuals (HD6-11 and HD14-18) and a concentration
of 0.4 μg/ml was selected in cultures from 8 individuals
(HD12-13 and HD19-24).
Figure 1 CI pattern in metaphases from DEB-induced lymphocyte cultures from a healthy donor and FA patient. Chromosomes were
stained in a 4% Giemsa solution. The images were observed with an optical microscope (Olympus CX31) and captured with a digital camera
(Nikon Sightds-smc), with the software DP20-5E microscope digital camera. (A) Selected metaphase from a HD lymphocyte culture exposed to
0.2 μg/ml of DEB for 48 h. One chromatid break can be seen (asterisk). (B) Selected metaphase from a FA patient lymphocyte culture exposed to
0.05 μg/ml of DEB for 48 h. High level of chromosome instability can be visualized, especially being important the tri and tetraradial figures
(arrow) that are the hallmark for the diagnosis of FA. It can also be seen a dicentric chromosome (head arrow) and 3 chromatid breaks (asterisks).
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Since DEB is a suspected carcinogen with unknown
risk, appropriate precautions were taken. All culture pro-
cedures were handled using appropriate gloves and in a
vertical laminar flow hood. As DEB is rapidly inactivated
by concentrated HCl, all disposable culture bottles and
pipettes were rinsed with HCl before being discarded.
Antioxidant treatments
We used two antioxidants, α-LA 20 μM [33] (Sigma)
and NAC 500 μM [10] (Sigma) at concentrations that
proved to be effective in in vitro studies, preferably with
lymphocytes. In addition, prospective studies were al-
ways performed to find the most efficient concentrations
(data not shown). α-LA and NAC concentrations used
in the present study are within the plasma concentra-
tions found in previous human pharmacokinetic studies
using these drugs [34,35]. α-LA was dissolved in 1%
dimetilsulfoxide (DMSO) in RPMI 1640 and NAC was
dissolved in RPMI 1640. α-LA was stored in the dark at
room temperature. NAC was stored at 4°C. The two anti-
oxidants were used from the same batch in all
experiments.
Antioxidant treatments in DEB-exposed lymphocyte cultures
from healthy donors
Two sets of experiments were done. In the first set,
lymphocyte cultures were pre-treated with α-LA 20 μM
1.5 h before DEB exposure. In the second set of experi-
ments lymphocyte cultures were pre-treated with NAC
500 μM, 1.5 h before DEB exposure. DMSO toxicity was
found to be absent within our experimental conditions.
Antioxidant treatments in spontaneous and DEB-exposed
lymphocyte cultures from FA patients
Three sets of experiments were done. In the first set,
lymphocyte cultures were treated with α-LA 20 μM for
48 h. In DEB-induced lymphocyte cultures α-LA was
added 1.5 h before DEB exposure. In the second, lym-
phocyte cultures were treated with NAC 500 μM for
48 h. In DEB-exposed lymphocyte cultures, NAC was
added 1.5 h before DEB exposure. In the last set, both
antioxidants were added simultaneously to lymphocyte
cultures, at the same concentrations, for 48 h. In DEB-
exposed lymphocyte cultures antioxidants were added
1.5 h before DEB exposure. DMSO toxicity was found to
be absent within our experimental conditions.
Cytogenetic analysis
After 3 days of culture, cells were harvested after 1 h of
incubation with colcemid (GIBCO) (4 μg/ml), followed
by hypotonic treatment with 75 mM KCl (Sigma) and
fixed 3 times in a 1:3 iced solution of acetic acid
(Merck): methanol (Merck). The resulting suspensions
were dropped onto microscope slides and stained for
5 min in a 4% Giemsa solution (Merck) diluted in phos-
phate buffer saline solution (Sigma).
Analysis was performed on 50–100 metaphases from
each experiment, by an independent scorer and in a
blinded fashion. Only when the mitotic index (MI) was
very low and the number of breaks was high, a mini-
mum of 22 metaphases was counted. Each cell was
scored for chromosome number and the number and
type of structural abnormalities. Gaps (acromatic areas
less than a chromatid in width) were excluded in the cal-
culation of chromosome breakage frequencies, and rear-
rangements (triradials and quadriradials, dicentrics and
ring chromosomes) were scored as two breaks.
Mitotic index
From the same microscope stained slides, used for chro-
mosome breakage analysis, a thousand cells were ran-
domly scored, distinguishing between interphase nuclei
and metaphase nuclei. MI was calculated as follows: num-
ber of metaphase nuclei /number of total nuclei.
Statistical analysis
Graph results are expressed as mean ± SEM and table
results are expressed as mean ± SD. Statistical compari-
son among groups was estimated using one-way ANOVA,
followed by the Bonferroni post hoc test, and compari-
son between two groups was estimated using paired t-test,
both with GraphPad Prism, version 5.0 software. P values
lower than 0.05 were considered as statistically significant.
Results
Effect of α-lipoic acid and N-acetylcysteine on
DEB-induced CI in lymphocyte cultures from healthy donors
As shown in Table 1, lymphocyte cultures from HD ex-
posed to DEB and pre-treated with α-LA or NAC showed
a reduction in the number of breaks per cell compared
to those only exposed to DEB (P> 0.05 and P< 0.05, re-
spectively). Noteworthy, two distinct groups can be con-
sidered concerning the protective effect: a group of
responders and another one of non-responders. Among
DEB-induced cultured lymphocytes pre-treated with α-LA
54% are responders whereas among those pre-treated with
NAC, 82% are responders. However, the response with
α-LA treatment is greater, while with NAC the potency
is not only lower but also more variable. Globally, the
percentage of Cl reduction in lymphocyte cultures pre-
treated with α-LA was 25% and with NAC was 20%.
Effect of α-lipoic acid, N-acetylcysteine and α-lipoic acid
plus N-acetylcysteine on spontaneous CI in lymphocyte
cultures from FA patients
As shown in Table 2, lymphocyte cultures from FA
patients treated with α-LA, NAC and α-LA plus NAC
showed a significant reduction in the number of breaks
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per cell, compared to cultures without antioxidant treat-
ment (P< 0.01, P< 0.01 and P< 0.01, respectively).
Comparing α-LA vs NAC treatments, no difference
(P> 0.05) was found in the reduction of the number of
breaks per cell. However, comparing both isolated α-LA
and NAC treatments with the combined α-LA plus
NAC treatment, the reduction in the number of breaks
per cell was highly significant (P< 0.05 and P< 0.01, re-
spectively). Globally, the percentage of reduction in
lymphocyte cultures treated with α-LA was 34% (P< 0.01),
with NAC was 40% (P< 0.01) and with α-LA plus NAC
was 58% (P< 0.001), as shown in Figure 2.
Table 2 Number of breaks per cell in cultured lymphocytes from FA patients
Mean number of breaks per cell
Patients Control group (n) α-LA 20 μM (n) % reduction NAC 500 μM (n) % reduction α-LA 20 μM +NAC 500 μM (n) % reduction
FA1 0.26 (100) 0.09 (100) 65.38 _ _ _ _
FA2 0.27 (100) 0.14 (100) 48.15 _ _ _ _
FA3 0.28 (100) 0.15 (100) 46.43 _ _ _ _
FA4 0.62 (91) 0.29 (92) 53.23 _ _ _ _
FA5 1.50 (100) 0.94 (100) 37.33 _ _ _ _
FA6 0.75 (100) 0.50 (76) 33.33 _ _ _ _
FA7 1.50 (50) 1.50 (50) 0.00 _ _ _ _
FA8 0.19 (100) 0.16 (50) 15.79 0.16 (50) 15.79 0.16 (50) 15.79
FA9 0.26 (50) 0.12 (50) 53.85 0.06 (50) 76.92 0.04 (50) 84.62
FA10 0.30 (50) 0.14 (50) 53.33 0.08 (50) 73.33 0.04 (50) 86.67
FA11 0.22 (50) 0.18 (50) 18.18 0.10 (50) 54.55 0.06 (50) 72.73
FA12 0.24 (50) 0.08 (50) 66.67 0.18 (50) 25.00 0.06 (50) 75.00
FA13 0.30 (50) 0.44 (50) 0.00 0.26 (50) 13.33 0.20 (50) 33.33
FA14 0.31 (100) _ _ 0.24 (50) 22.58 0.20 (50) 35.48
Mean± SD 0.500 ± 0.452 0.364 ± 0.417 0.154± 0.078 0.109 ± 0.075
In control group no antioxidant treatment was done. The effect of the antioxidants was calculated by the percentage of reduction of the number of breaks per
cell in the α-LA, NAC and α-LA plus NAC treatments relatively to control group. - Unavailable data. Abbreviations are explained in Table 1. Paired t-test: Control
group vs α-LA 20 μM P< 0.01; Control group vs NAC 500 μM P< 0.01; Control group vs α-LA 20 μM+NAC 500 μM P< 0.01; α-LA 20 μM vs α-LA 20 μM+NAC
500 μM P< 0.05; NAC 500 μM vs α-LA 20 μM+NAC 500 μM P< 0.01.
Table 1 Number of DEB-induced breaks per cell in cultured lymphocytes from healthy donors
Number of breaks per cell
Healthy donors Control group (n) α-LA 20 μM (n) % reduction Healthy donors Control group (n) NAC 500 μM (n) % reduction
HD1 0,09 (100) 0,09 (100) 0,00 HD14 0,20 (41) 0,14 (50) 30,00
HD2 0,09 (100) 0,06 (100) 33,33 HD15 0,14 (50) 0,12 (50) 14,29
HD3 0,07 (100) 0,07 (100) 0,00 HD16 0,12 (50) 0,04 (50) 66,67
HD4 0,08 (100) 0,03 (100) 62,50 HD17 0,10 (50) 0,12 (50) 0,00
HD5 0,04 (100) 0,01 (100) 75,00 HD18 0,12 (50) 0,08 (50) 33,33
HD6 0,44 (100) 0,12 (100) 72,73 HD19 0,22 (50) 0,16 (50) 27,27
HD7 0,12 (100) 0,11 (100) 8,33 HD20 0,32 (50) 0,14 (50) 56,25
HD8 0,08 (100) 0,09 (100) 0,00 HD21 0,14 (50) 0,10 (50) 28,57
HD9 0,09 (100) 0,10 (100) 0,00 HD22 1,14 (50) 1,00 (50) 12,28
HD10 0,10 (100) 0,11 (100) 0,00 HD23 0,18 (51) 0,12 (50) 33,33
HD11 0,18 (50) 0,08 (100) 55,56 HD24 0,13 (100) 0,20 (50) 0,00
HD12 0,19 (53) 0,22 (100) 0,00 _ _ _ _
HD13 0,15 (100) 0,06 (100) 60,00 _ _ _ _
Mean± SD 0.132± 0.102 0.088 ± 0.051 Mean± SD 0.255 ± 0.300 0.202± 0.268
In control group no antioxidant treatment was done. The effect of the antioxidants was calculated by the percentage of reduction of the number of breaks per
cell in α-LA and NAC treatments relatively to control group. - Unavailable data; α-LA indicates α-lipoic acid; NAC indicates N-acetylcysteine; n indicates the number
of cells analyzed. Paired t-test: Control group vs NAC 500 μM P< 0.05.
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Concerning the α-LA antioxidant effect two distinct
groups were, once more, observed: responders and non-
responders; in a total of 13 lymphocyte cultures, 85%
were responders, and in two of them CI decreased to
normal values (below 0.1). In NAC and α-LA plus NAC
treated cultures only responders were observed. Besides,
in two cultures treated with NAC and four treated with
α-LA plus NAC a decrease in the number of breaks per
cell to normal values was also observed (Table 2).
Effect of α-lipoic acid, N-acetylcysteine and α-lipoic acid plus
N-acetylcysteine on spontaneous CI in lymphocyte cultures
from a particular group of FA patients - mosaics and chimera
Considering the cytogenetic diagnosis of the patients re-
ferred in Table 2, patients FA9 and FA10 were classified
as mosaics and FA11 as a post-transplant chimera. Thus,
they have a higher frequency of normal cells. What we can
see is that, for these patients, the number of breaks per cell
decreased to normal values with α-LA plus NAC treatment,
which translates in an even greater reduction in the number
of breaks per cell, of about 80%, P< 0.001 (Figure 3).
Effect of α-lipoic acid plus N-acetylcysteine on cell cycle
progression in cultured lymphocytes from FA patients
MI was measured in lymphocyte cultures submitted to
the three types of antioxidant treatments. The results dis-
played in Table 3 show that, in average, the α-LA treat-
ment increased the MI from 0.17 (in control group) to
0.18, while NAC treatment increased to 0.19, and, most
importantly, the combined use of both antioxidants resulted
in a significant increase to 0.27, which clearly demonstrates
that α-LA plus NAC treatment significantly increased
the MI of cultured lymphocytes, P< 0.05 (Figure 4).
Effect of α-lipoic acid, N-acetylcysteine and α-lipoic acid
plus N-acetylcysteine on DEB- induced CI in lymphocyte
cultures from FA patients
As shown in Table 4, lymphocyte cultures from FA
patients pre-treated with α-LA, NAC, and α-LA plus
Figure 3 Effect of α-LA, NAC and α-LA+NAC on chromosome
breaks in cultured lymphocytes from FA mosaics/chimeras.
Lymphocyte cultures were treated with 20 μM α-LA, 500 μM NAC,
and both antioxidants simultaneously at the same concentrations.
The results are presented as the relative mean of breaks per cell
(percentage of control values). Comparison of the relative mean of
breaks/cell was made between control group and each antioxidant
treatment (*** P< 0.001 and **P< 0.01) and between treatments
(P> 0.05). Results are representative of the mean of 3 experiments
depicted from Table 2.
Table 3 Determination of mitotic index in cultured








α-LA 20 μM +
NAC 500 μM
FA8 0,013 0,019 0,023 0,025
FA9 0,029 0,028 0,033 0,037
FA10 0,019 0,019 0,009 0,027
FA11 0,009 0,006 0,013 0,014
FA13 0,011 0,019 0,026 0,036
FA14 0,019 0,018 0,012 0,020
Mean± SD 0.017 ± 0.007 0.018± 0.007 0.019 ± 0.009 0.026± 0.009
In control group no antioxidant treatment was done. Abbreviations are
explained in Table 1. Paired t-test: Control group vs α-LA 20 μM+NAC 500 μM
P< 0.05.
Figure 2 Effect of α-LA, NAC and α-LA+NAC on chromosome
breaks in cultured lymphocytes from FA patients. Lymphocyte
cultures were treated with 20 μM α-LA, 500 μM NAC, and both
antioxidants simultaneously at the same concentrations. The results
are presented as the relative mean of breaks per cell (percentage of
control values). Comparison of the relative mean of breaks/cell was
made between control group and each antioxidant treatment
(*** P< 0.001 and **P< 0.01) and between treatments (P> 0.05).
Results are representative of the mean of 14 experiments depicted
from Table 2.
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NAC, and after exposure to DEB, showed a significant
reduction in the number of breaks per cell compared to
the control group (P< 0.05, P< 0.05 and P< 0.05, re-
spectively). Comparing α-LA vs NAC treatments (P> 0.05),
α-LA vs α-LA plus NAC treatments (P< 0.05) and NAC
vs α-LA plus NAC treatments (P> 0.05) no differences
were found in the reduction in the number of breaks per
cell. Globally, the percentage of reduction in lymphocyte
cultures pre-treated with α-LA was 28% (P> 0.05), with
NAC was 54% (P< 0.001) and with α-LA plus NAC was
60% (P< 0.001), as shown in Figure 5. Once more, two
distinct groups can be considered, a group of responders
and another one of non-responders. In a total of 12 α-LA
pre-treated lymphocyte cultures, 67% were responders,
while in a total of 7 NAC pre-treated lymphocyte cul-
tures, 86% were responders. In α-LA plus NAC pre-
treated cultures 100% were responders. In a culture from
one patient belonging to this last group, the number of
breaks per cell decreased to values considered normal
(below 0.1).
Discussion
In the present work we evaluated the protective effect of
α-LA and NAC and, more importantly, the protective ef-
fect of a cocktail with these two compounds, against
spontaneous and DEB-induced CI in lymphocyte cul-
tures from FA patients. The obtained results provide an
important and novel finding: it was clearly evident, for
the first time, that the concomitant exposure to α-LA
and NAC can drastically improve the genetic stability in
lymphocytes from FA patients, in vitro.
Various reports have previously shown mitochondrial
dysfunctions in FA cells, including distorted mitochon-
drial structures and peroxyredoxin 3 deregulation in FA-
A, FA-C and FA-G cells[18] and mitochondrial matrix
densification in FA-A fibroblasts after 8-methoxypsolaren
photoreaction or UVA irradiation [17]. It is known that
mitochondrial dysfunctions ultimately lead to a defect in
energy transduction, with increased formation of ROS,
which, by itself, can lead to lower cellular energy charge,
oxidative modification of DNA, protein and lipids.
In addition, there is also a possibility of a positive
Figure 4 Effect of α-LA+NAC on mitotic index of cultured
lymphocytes from FA patients. Lymphocyte cultures were treated
with 20 μM α-LA plus 500 μM NAC. Mitotic index was evaluated as
described in “methods” and the results are presented as absolute
frequencies depicted from Table 3 (*P< 0.05).
Table 4 Number of DEB-induced breaks per cell in cultured lymphocytes from FA patients
Mean number of breaks per cell
Patients Control group (n) α-LA 20 μM (n) % reduction NAC 500 μM (n) % reduction α-LA 20 μM +NAC 500 μM (n) % reduction
FA1 4.36 (100) 1.16 (100) 73.39 _ _ _ _
FA2 1.85 (100) 1.99 (100) 0.00 _ _ _ _
FA3 1.80 (100) 1.50 (100) 16.67 _ _ _ _
FA4 0.78 (100) 0.57 (100) 26.92 _ _ _ _
FA6 1.00 (80) 1.16 (56) 0.00 _ _ _ _
FA7 7.20 (25) 5.50 (22) 23.61 _ _ _ _
FA8 1.74 (50) 2.10 (50) 0.00 1.16 (50) 33.33 0.70 (50) 59.77
FA9 0.60 (50) 0.30 (50) 50.00 0.22 (50) 63.33 0.30 (50) 50.00
FA10 1.32 (50) 1.60 (50) 0.00 1.60 (50) 0.00 _ _
FA11 0.40 (100) 0.10 (50) 75.00 0.14 (44) 65.00 0.24 (45) 40.00
FA12 3.76 (50) _ _ _ _ 1.48 (50) 60.64
FA13 5.06 (50) _ _ 0.20 (50) 96.05 2.26 (50) 55.34
FA14 2.26 (50) 1.46 (37) 35.40 1.28 (50) 43.36 1.10 (50) 51.33
FA15 4.31 (100) 0.14 (50) 96.75 0.14 (50) 96.75 0.02 (50) 99.54
Mean± SD 2.603 ± 2.019 1.465 ± 1.444 0.677± 0.641 0.871 ± 0.799
In control group no antioxidant treatment was done and lymphocytes were exposed to DEB 0.05 μg/ml. The effect of the antioxidants was calculated by the
percentage of reduction of the number of breaks per cell in the α-LA, NAC and α-LA plus NAC treatments relatively to control group. - Unavailable data.
Abbreviations are explained in Table 1. Paired t-test: Control group vs α-LA 20 μM P< 0.05; Control group vs NAC 500 μM P< 0.05; Control group vs α-LA
20 μM+NAC 500 μM P< 0.05.
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feedback cycle between ROS formation and mitochon-
drial damage, exacerbating the processes of cellular dys-
function (reviewed in Tarnopolsky) [26]. It was already
demonstrated that GSH protects mitochondrial DNA
from oxidative damage in human lymphocytes and that
GSH depletion increases their susceptibility to mitochon-
drial DNA damage [36]. It is noteworthy that GSH levels
are downregulated in FA patients [37]. Therefore, it may
be postulated that such imbalance in the redox state of
FA cells can be counteracted by antioxidants, in particu-
lar mitochondrial nutrients, like α-LA, and other antioxi-
dants that can replace or replenish GSH levels, like NAC,
as it was demonstrated in the present study.
Hypersensitivity of lymphocytes to the clastogenic ef-
fect of DEB is a common biomarker of FA. Previous
studies have shown that DEB acts as a bifunctional alkyl-
ating agent, exhibiting both inter-strand and intra-strand
DNA cross-linking ability [38] and that is redox-active,
generating ROS that can damage DNA [8]. Furthermore,
acute exposure of normal human lymphocytes to DEB is
associated with GSH and ATP depletion [10], which in-
dicates that DEB can also cause mitochondrial dysfunc-
tion. The exacerbation of OS and DNA cross-linking in
FA lymphocytes, through DEB-mediated effects, can re-
produce damaging conditions present in severe clinical
FA situations, which theoretically extends the applicabil-
ity of the present results from bench to bedside.
Under the present experimental conditions, the α-LA
effect, measured by the reduction in the number of breaks
per cell, was similar (around 30%) in the three studied
groups: DEB-induced lymphocyte cultures from HD and
spontaneous and DEB-induced cultures from FA pa-
tients (Figure 6A). This indicates that α-LA effect was
independent of DEB exposure or health condition of the
studied subject. On the other hand, we verified that
NAC effect in these same three groups seems to be
dependent of the treatment and health condition
(Figure 6B), since the reduction in the number of breaks
per cell was greater in DEB-induced lymphocytes from
FA patients. These results are in agreement with previ-
ous studies, showing that NAC inhibits ROS production
and apoptosis induced by DEB in human lymphoblasts
[8] and that NAC protects human lymphocytes from
acute in vitro exposure to DEB [10]. Last but not least,
we also verified that the effect of the combined use of
α-LA plus NAC is independent of DEB exposure, as
shown in Figure 6C, with a 60% of reduction in the
number of breaks per cell in both groups of FA patients,
and even more effective in cultures from FA patients
with higher frequency of normal cells, such as FA
mosaics or FA chimera, in which the reduction was of
about 80%. Furthermore, the measurement of spontan-
eous chromosomal breaks was of particular importance,
as it rules out the possibility that the main anti-
chromosomal break effect of α-LA and NAC is due to a
direct interaction of these agents with DEB.
Additionally, MI was measured in lymphocyte cultures
from FA patients submitted to all antioxidant treat-
ments. The reason for this assay was to evaluate if the
decrease in CI was due to an increase in mitotic prolif-
eration, with a consequent shortening of the cell cycle
arrest in G2, as it was demonstrated for α-tocopherol by
Pincheira et al [23]. What we observed is that MI in-
creased in all antioxidant treatments, especially with
α-LA plus NAC treatment, suggesting a relation be-
tween a decrease in CI and a shortening of cell arrest in
G2. We cannot exclude, however, that, in lymphocyte
cultures from mosaic and chimera patients, the increase
in MI can be due to a positive selection of normal cells,
with a consequent increase in apoptosis.
The results now obtained suggest that α-LA plus NAC
cocktail may be useful to keep chromosome stability in
FA patients, which can be very important to block or
delay the progression of the disease. This cocktail may
be even more effective when applied to FA mosaics and
FA chimeras, after bone marrow transplant, as we ob-
served in vitro. It must be stressed that bone marrow
transplant only resolves bone marrow failure, curing
the hematological manifestations. However, CI is not
Figure 5 Effect of α-LA, NAC and α-LA+NAC on chromosome
breaks in DEB-induced cultured lymphocytes from FA patients.
Lymphocyte cultures were pre-treated with 20 μM α-LA, 500 μM
NAC, and both antioxidants simultaneously at the same
concentrations, 1.5 h before exposure to DEB 0.05 μg/ml for 48 h.
The results are presented as the relative mean of breaks per cell
(percentage of control values). Comparison of the relative mean of
breaks/cell was made between control group and each antioxidant
treatment (*** P< 0.001) and between treatments (P> 0.05). Results
are representative of the mean of 14 experiments depicted from
Table 4.
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mitigated, and predisposition to cancer, other than leu-
kemia, persists, especially solid tumors [3,39,40]. Thus,
controlling CI in FA patients after bone marrow trans-
plant could be very important.
Additionally to increasing chromosomal stability, α-LA
has also important cellular roles in the regulation of
gene transcription, inhibition of the activation of NF-kB
(nuclear factor kappa-light-chain-enhancer of activated
B cells) and activating protein 1, [41,42] while NAC ap-
parently modulates cytokine concentrations, as interleukin
(IL)-1, TNF-α (tumor necrosis factor-alpha) and IFN-γ
(interferon-gamma) [30]. These pharmacological effects
may further contribute for the therapeutic usefulness of
α-LA plus NAC cocktail by avoiding the inflammatory
process, mostly frequent in FA children patients [43,44].
Of note, some studies concerning the immunological re-
sponse of FA patients demonstrated lymphocyte dysfunc-
tion and high levels of TNF-α [45]. Low production of
IL including IL1, IL2, and IL6, as well as IFN-γ and
granulocyte-macrophage colony stimulating factor have
also been reported [46].
The present work might open a novel strategy to deal
with FA disease. The choice of these antioxidants, apart
from their pharmacodynamics, takes into account that
both α-LA and NAC have been already approved for safe
human use with minimal or no adverse effect, showing
an excellent safety profile. NAC has been in clinical use
for more than 30 years, in conditions characterized by
depletion of GSH or OS, as cancer, AIDS, pulmonary
diseases, heart diseases, as well as in acetaminophen
overdose [30,47,48]. Thus, in conditions characterized by
a chronic excessive OS and in clinical situations where
GSH levels are decreased, NAC appears to be a highly
effective drug, and may be also recommendable in the
prevention/treatment of FA. α-LA has been used, espe-
cially in Germany, for over 30 years, in the treatment of
diabetic polyneuropathies. Several evidences support a
role for α-LA as a mitigator of OS in type 2 diabetes
[49], this drug being also used in the treatment of ath-
erosclerosis, cardiovascular diseases, cataracts, neurode-
generative diseases, liver diseases and AIDS [50]. Besides
the well-known characteristics as antioxidant and as
mitochondrial nutrient, α-LA can be administrated or-
ally, since it is easily absorbed in the stomach, it crosses
blood–brain barrier, due to its amphipathic properties,
and is not toxic at doses used for prophylactic and thera-
peutic purposes [50]. Furthermore, α-LA and NAC are
also inexpensive drugs, which is a great advantage com-
pared with other proposed therapies, namely gene ther-
apy [51], and others that are now available, such as
androgen therapy [52], allowing an easy access by all FA
patients. Therefore, this cocktail may be immediately
tested in phase III clinical trials for treating chromosome
instability. Moreover, a FA prevention trial could also be
Figure 6 Comparison between the different studied groups according to the antioxidant treatments. Comparative analysis of the effect of
α-LA (A), NAC (B) and α-LA plus NAC treatments was performed between lymphocyte cultures from the four studied groups: healthy donors,
FA patients (spontaneous breaks), FA patients (DEB-induced breaks) and FA mosaic/chimera patients. All values were depicted from Figures 2,
3 and 5.
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designed to see whether the administration of these
drugs can prevent the development of leukemia, in an
initial phase, and solid tumors in an advanced form of
the disease. The proposed clinical trial, using the com-
bined administration of α-LA and NAC also poses a few
challenges. FA is a rare disease, which implies a small
population of patients, most of them children or teen-
agers. This requires a strong adhesion to the new ap-
proach by parents and family. In addition, the efficacy
may vary among FA patients, as we observed by the
presence of responders and non responders. However,
this challenge may be easily overcome by studying the
response of each individual in an in vitro assay before
starting the therapy.
A large number of epidemiological studies have shown
health improvements in association with the consump-
tion of dietary antioxidants as part of food. Several studies
have shown that the provision of individual antioxidants
as supplements are either ineffective [53], or can be
deleterious to health [54]. Part of the reason that large
doses of exogenous single antioxidants can be deleteri-
ous is that every antioxidant can also function as a pro-
oxidant and antioxidants function optimally when several
are present and can function as redox couples [26]. This
fact may explain the success of our cocktail, α-LA plus
NAC. They act as an effective redox couple, and in two
distinct but closely related processes: α-LA acts as a mito-
chondrial nutrient and NAC as a GSH precursor and dir-
ect ROS scavenger.
Conclusions
The present study provides an important and novel find-
ing that may have immediate clinical applicability: it was
clearly evident, for the first time, that the concomitant
exposure to α-LA and NAC can drastically improve the
genetic stability in lymphocytes from FA patients. Since
the available information points to an association of cel-
lular phenotype and clinical features with the occurrence
of both cancer-proneness and OS in FA disorder, these
results suggest that α-LA plus NAC can be an effective
antioxidant prophylactic cocktail to be applied, in vivo,
in FA patients, with a consequent block or delay in their
characteristic bone marrow failure and early cancer de-
velopment. On the pre-clinical perspective, mechanistic
studies are still required to understand why these antiox-
idants together are so effective in the reduction of CI in
lymphocytes from FA patients, providing, this way, fur-
ther clues to know what is falling in FA cells.
Abbreviations
8-OHdG: 8-hydroxy-2’-deoxyguanosine; 8-oxoG: 7,8-dihydro-8-
hydroxyguanine; AIDS: Acquired immune deficiency syndrome;
CI: Chromosome instability; DEB: Diepoxybutane; DMSO: Dimetilsulfoxide;
FA: Fanconi anemia; GSH: Reduced glutathione; HD: Healthy donor;
IL: Interleukin; INF-γ: Interferon-gamma; MI: Mitotic index; NAC:
N-acetylcysteine; NF-kB: Nuclear factor kappa-light-chain-enhancer of
activated B cells; OS: Oxidative stress; PRDX3: Peroxiredoxin 3; ROS: Reactive
oxygen species; TNF-α: Tumor necrosis factor alpha; α-LA: α-lipoic acid.
Competing interests
The authors declare no competing financial interest.
Acknowledgements
Filipa Ponte is thankful to Fundação para a Ciência e Tecnologia (FCT) for her
PhD grant (SFRH / BD / 39903 / 2007). Authors wish to thank to volunteers
that provided blood samples, through the Service of Hematology from the
Hospital Geral de Santo António and Institute of Biomedical Sciences Abel
Salazar, and to FA patients and their families. A special appreciation to all the
clinicians around the country that provided the access to blood samples
from FA children. Authors also thank to Doctor Graça Porto for the helpful
discussion.
Author details
1Chemistry and Technology Network (REQUIMTE), Laboratory of Toxicology,
Department of Biological Sciences, Faculty of Pharmacy, University of Porto,
Porto, Portugal. 2Cytogenetics Laboratory, Department of Microscopy,
Institute of Biomedical Sciences Abel Salazar (ICBAS), Porto, Portugal.
3Hemato-oncologic Unity, Hospital São João (HSJ), Porto, Portugal. 4Service
of Hematology of Hospital Center of Porto (CHP), Porto, Portugal. 5Unity of
Pediatric Hematology of CHP, Porto, Portugal.
Authors’ contributions
FP designed experiments, performed research, analyzed data and drafted the
manuscript. RS performed research and analyzed data. APF, CG and JB
provided blood samples and clinical data from FA patients, analyzed the
experimental data. BP and FC coordinated the study, designed experiments,
analyzed data, critically revised the manuscript and gave final approval of the
version to be published. All authors read and approved the final manuscript.
Received: 8 February 2012 Accepted: 16 May 2012
Published: 16 May 2012
References
1. Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF,
Hanenberg H, Auerbach AD: A 20-year perspective on the International
Fanconi Anemia Registry (IFAR). Blood 2003, 101:1249–1256.
2. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A:
Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 2011,
43:142–146.
3. Auerbach AD: Fanconi anemia and its diagnosis. Mutat Res/Fundam Mol
Mech Mutagenesis 2009, 668:4–10.
4. Pagano G, Aiello Talamanca A, Castello G, Pallardó FV, Zatterale A, Degan P:
Oxidative stress in Fanconi anaemia: from cells and molecules toward
prospects in clinical management. Biol Chem In press.
5. Korkina LG, Deeva IB, De Biase A, Iaccarino M, Oral R, Warnau M, Pagano G:
Redox-dependent toxicity of diepoxybutane and mitomycin C in sea
urchin embryogenesis. Carcinogenesis 2000, 21:213–220.
6. Vlachodimitropoulos D, Norppa H, Autio K, Catalan J, Hirvonen A, Tasa G,
Uuskula M, Demopoulos NA, Sorsa M: GSTT1-dependent induction of
centromere-negative and -positive micronuclei by 1,2:3,4-diepoxybutane
in cultured human lymphocytes. Mutagenesis 1997, 12:397–403.
7. Spano M, Cordelli E, Leter G, Pacchierotti F: Diepoxybutane cytotoxicity on
mouse germ cells is enhanced by in vivo glutathione depletion: a flow
cytometric approach. Mutat Res-Fund Mol M 1998, 397:37–43.
8. Yadavilli S, Martinez-Ceballos E, Snowden-Aikens J, Hurst A, Joseph T,
Albrecht T, Muganda PM: Diepoxybutane activates the mitochondrial
apoptotic pathway and mediates apoptosis in human lymphoblasts
through oxidative stress. Toxicology in Vitro 2007, 21:1429–1441.
9. Michaelson-Richie ED, Loeber RL, Codreanu SG, Ming X, Liebler DC,
Campbell C, Tretyakova NY: DNA − protein cross-linking by
1,2,3,4-diepoxybutane. J Proteome Res 2010, 9:4356–4367.
10. Ponte F, Carvalho F, Porto B: Protective effect of acetyl-l-carnitine and
α-lipoic acid against the acute toxicity of diepoxybutane to human
lymphocytes. Toxicology 2011, 289:52–58.
11. Nordenson I: Effect of superoxide dismutase and catalase on
spontaneously occurring chromosome breaks in patients with Fanconi's
anemia. Hereditas 1977, 86:147–150.
Ponte et al. Orphanet Journal of Rare Diseases 2012, 7:28 Page 10 of 11
http://www.ojrd.com/content/7/1/28
12. Joenje H, Arwert F, Eriksson AW, de Koning H, Oostra AB: Oxygen-
dependence of chromosomal aberrations in Fanconi's anaemia. Nature
1981, 290:142–143.
13. Joenje H, Oostra B: Effect of oxygen tension on chromosomal aberrations
in Fanconi anaemia. Hum Genet 1983, 65:99–101.
14. Kruyt FAE, Hoshino T, Liu JM, Joseph P, Jaiswal AK, Youssoufian H:
Abnormal microsomal detoxification implicated in Fanconi anemia
group C by interaction of the FAC protein with NADPH cytochrome
P450 reductase. Blood 1998, 92:3050–3056.
15. Cumming RC, Lightfoot J, Beard K, Youssoufian H, O'Brien PJ, Buchwald M:
Fanconi anemia group C protein prevents apoptosis in hematopoietic
cells through redox regulation of GSTP1. Nat Med 2001, 7:814–820.
16. Futaki M, Igarashi T, Watanabe S, Kajigaya S, Tatsuguchi A, Wang J, Liu JM:
The FANCG Fanconi anemia protein interacts with CYP2E1: possible role
in protection against oxidative DNA damage. Carcinogenesis 2002, 23:67–72.
17. Rousset S, Nocentini S, Rouillard D, Baroche C, Moustacchi E: Mitochondrial
alterations in Fanconi anemia fibroblasts following ultraviolet A or
psoralen photoactivation. Photochem Photobiol 2002, 75:159–166.
18. Mukhopadhyay SS, Leung KS, Hicks MJ, Hastings PJ, Youssoufian H, Plon SE:
Defective mitochondrial peroxiredoxin-3 results in sensitivity to
oxidative stress in Fanconi anemia. J Cell Biol 2006, 175:225–235.
19. Degan P, Bonassi S, Caterina MD, Korkina LG, Pinto L, Scopacasa F,
Zatterale A, Calzone R, Pagano G: In vivo accumulation of 8-hydroxy-2
'-deoxyguanosine in DNA correlates with release of reactive oxygen
species in Fanconi's anaemia families. Carcinogenesis 1995, 16:735–742.
20. Castillo P, Bogliolo M, Surralles J: Coordinated action of the Fanconi
anemia and ataxia telangiectasia pathways in response to oxidative
damage. DNA Repair 2011, 10:518–525.
21. Dallapiccola B, Porfirio B, Mokini V, Alimena G, Isacchi G, Gandini E: Effect of
oxidants and antioxidants on chromosomal breakage in Fanconi anemia
lymphocytes. Hum Genet 1985, 69:62–65.
22. Porfirio B, Ambroso G, Giannella G, Isacchi G, Dallapiccola B: Partial
correction of chromosome instability in Fanconi anemia by
desferrioxamine. Hum Genet 1989, 83:49–51.
23. Pincheira J, Bravo M, Santos MJ, de la Torre C, López-Sáez JF: Fanconi
anemia lymphocytes: effect of dl-α-tocopherol (Vitamin E) on chromatid
breaks and on G2 repair efficiency. Mutat Res 2001, 461:265–271.
24. Zhang Q-S, Eaton L, Snyder ER, Houghtaling S, Mitchell JB, Finegold M,
Van Waes C, Grompe M: Tempol protects against oxidative damage and
delays epithelial tumor onset in Fanconi anemia mice. Cancer Res 2008,
68:1601–1608.
25. Zhang Q-S, Marquez-Loza L, Eaton L, Duncan AW, Goldman DC, Anur P,
Watanabe-Smith K, Rathbun RK, Fleming WH, Bagby GC, Grompe M:
Fancd2−/− mice have hematopoietic defects that can be partially
corrected by resveratrol. Blood 2010, 116:5140–5148.
26. Tarnopolsky MA: The mitochondrial cocktail: rationale for combined
nutraceutical therapy in mitochondrial cytopathies. Adv Drug Deliv Rev
2008, 60:1561–1567.
27. Pallardó F, Lloret A, Lebel M, d’Ischia M, Cogger V, Le Couteur D, Gadaleta
M, Castello G, Pagano G: Mitochondrial dysfunction in some oxidative
stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome,
Fanconi Anaemia and Werner Syndrome. Biogerontology 2010,
11:401–419.
28. Prahalathan C, Selvakumar E, Varalakshmi P, Kumarasamy P, Saravanan R:
Salubrious effects of lipoic acid against adriamycin-induced
clastogenesis and apoptosis in Wistar rat bone marrow cells. Toxicology
2006, 222:225–232.
29. Dadhania VP, Tripathi DN, Vikram A, Ramarao P, Jena GB: Intervention of
α-lipoic acid ameliorates methotrexate-induced oxidative stress and
genotoxicity: a study in rat intestine. Chem Biol Interact 2010, 183:85–97.
30. Kelly GS: Clinical applications of N-acetylcysteine. Altern Med Rev 1998,
3:114–127.
31. Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso M,
Massa E, Mocci M, Serpe R: Antioxidant agents are effective in inducing
lymphocyte progression through cell cycle in advanced cancer patients:
assessment of the most important laboratory indexes of cachexia and
oxidative stress. J Mol Med 2003, 81:664–673.
32. Zembron-Lacny A, Slowinska-Lisowska M, Szygula Z, Witkowski K, Szyszka K:
The comparison of antioxidant and hematological properties of
N-acetylcysteine and alpha-lipoic acid in physically active males. Physiol
Res 2009, 58:855–861.
33. Han D, Handelman G, Marcocci L, Sen CK, Roy S, Kobuchi H, Tritschler HJ,
Flohe L, Packer L: Lipoic acid increases de novo synthesis of cellular
glutathione by improving cystine utilization. Biofactors 1997, 6:321–338.
34. Teichert J, Hermann R, Ruus P, Preiss R: Plasma kinetics, metabolism, and
urinary excretion of Alpha-Lipoic acid following oral administration in
healthy volunteers. J Clin Pharmacol 2003, 43:1257–1267.
35. Brown M, Bjorksten A, Medved I, McKenna M: Pharmacokinetics of
intravenous &lt;i&gt;N -acetylcysteine in men at rest and during exercise.
Eur J Clin Pharmacol 2004, 60:717–723.
36. Hollins DL, Suliman HB, Piantadosi CA, Carraway MS: Glutathione regulates
susceptibility to oxidant-induced mitochondrial DNA damage in human
lymphocytes. Free Radic Biol Med 2006, 40:1220–1226.
37. Pagano G, Degan P, d'Ischia M, Kelly FJ, Pallardó FV, Zatterale A, Anak SS,
Akişık EE, Beneduce G, Calzone R, et al: Gender- and age-related
distinctions for the in vivo prooxidant state in Fanconi anaemia patients.
Carcinogenesis 2004, 25:1899–1909.
38. Millard JT, Hanly TC, Murphy K, Tretyakova N: The 5‘-GNC site for DNA
interstrand cross-linking is conserved for Diepoxybutane Stereoisomers.
Chem Res Toxicol 2005, 19:16–19.
39. Alter B, Kupfer G: Fanconi Anemia. In GeneReviews. Edited by Pagon RA, Bird
TD, Dolan CR, Stephens K. Seattle: University of Washington, Seattle; 2011.
40. Spanier G, Pohl F, Giese T, Meier JK, Koelbl O, Reichert TE: Fatal course of
tonsillar squamous cell carcinoma associated with Fanconi anaemia: A
mini review. J Craniomaxillofac Surg In press.
41. Shay K, Moreau RF, Smith EJ, Hagen TM: Is α-lipoic acid a scavenger of
reactive oxygen species in vivo? Evidence for its initiation of stress
signaling pathways that promote endogenous antioxidant capacity.
IUBMB Life 2008, 60:362–367.
42. Mizuno M, Packer L: Effects of α-Lipoic acid and Dihydrolipoic acid on
expression of proto-oncogene c-fos. Biochem Biophys Res Commun 1994,
200:1136–1142.
43. Myers KC, Bleesing JJ, Davies SM, Zhang X, Martin LJ, Mueller R, Harris RE,
Filipovich AH, Kovacic MB, Wells SI, Mehta PA: Impaired immune function
in children with Fanconi anaemia. Br J Haematol 2011, 154:234–240.
44. Liu Y, Ballman K, Li D, Khan S, Derr-Yellin E, Shou W, Haneline LS: Impaired
function of Fanconi anemia type C-deficient macrophages. J Leukoc Biol In press.
45. Rosselli F, Sanceau J, Gluckman E, Wietzerbin J, Moustacchi E: Abnormal
lymphokine production: a novel feature of the genetic disease Fanconi
anemia. II. In vitro and in vivo spontaneous overproduction of tumor
necrosis factor alpha. Blood 1994, 83:1216–1225.
46. Roxo PJ, Arruda LK, Nagao AT, Carneiro-Sampaio MM, Ferriani VP: Allergic
and immunologic parameters in patients with Fanconi's anemia. Int Arch
Allergy Immunol 2001, 125:349–355.
47. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA: N-Acetylcysteine—
a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol
2007, 7:355–359.
48. Millea PJ: N-acetylcysteine: multiple clinical applications. Am Fam
Physician 2009, 80:265–269.
49. Golbidi S, Laher I: Antioxidant therapy in human endocrine disorders.
Med Sci Monit 2010, 16:RA9–RA24.
50. Bilska A, Wlodek L: Lipoic acid - the drug of the future? Pharmacol Rep
2005, 57:570–577.
51. Tolar J, Becker S, Clapp D, Hanenberg H, Heredia C, Kiem H-P, Navarro S,
Qasba P, Rio P, Schmidt M, et al: Gene Therapy for Fanconi anemia: one
step closer to the clinic. Hum Gene Ther 2012, 23:141-144.
52. Scheckenbach K, Morgan M, Filger-Brillinger J, Sandmann M, Strimling B,
Scheurlen W, Schindler D, Göbel U, Hanenberg H: Treatment of the bone
marrow failure in Fanconi anemia patients with danazol. Blood Cells Mol Dis
2012, 48:128–131.
53. Jialal I, Devaraj S: Scientific evidence to support a vitamin e and heart
disease health claim: research needs. J Nutr 2005, 135:348–353.
54. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold J, Ross C, Arnold A,
Sleight P, Probstfield J, Dagenais G: Effects of long-term vitamin e
supplementation on cardiovascular events and cancer: a randomized
controlled trial. JAMA 2005, 293:1338–1347.
doi:10.1186/1750-1172-7-28
Cite this article as: Ponte et al.: Improvement of genetic stability in
lymphocytes from Fanconi anemia patients through the combined
effect of α-lipoic acid and N-acetylcysteine. Orphanet Journal of Rare
Diseases 2012 7:28.
Ponte et al. Orphanet Journal of Rare Diseases 2012, 7:28 Page 11 of 11
http://www.ojrd.com/content/7/1/28
